The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study

Urquidi, Cinthya; Santelices, Emilio; Lagomarcino, Anne J.; Valenzuela, Marı́a Teresa; Larrañaga, Nicolás; González, Emilio B.; Pavez, Axel; Wosiack, Amanda; Maturana, Marcela; Moller, Paulina; Torres, Juan Pablo; Muñoz, Sergio; O’Ryan, Miguel

doi:10.1016/j.vaccine.2023.03.060

Cited by 4 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The planning and type of NPIs were very different from country to country. Moreover, when the implementation of NPIs was similar in type and month of intervention, definitive conclusions could not be drawn, mainly due to the complexity of efficacy assessments [ 64 , 65 ]. On the other hand, similar findings had already been reported in the past when the role of NPIs in controlling influenza epidemics was studied [ 66 ].…”

Section: Reasons For Variations In Epidemiology Of Non-sars-cov-2 Vir...mentioning

confidence: 99%

Epidemiology of Respiratory Infections during the COVID-19 Pandemic

Principi

Autore

Ramundo

et al. 2023

Viruses

View full text Add to dashboard Cite

To face the COVID-19 outbreak, a wide range of non-pharmaceutical interventions (NPIs) aimed at limiting the spread of the virus in communities, such as mask-wearing, hand hygiene, social distancing, travel restrictions, and school closures, were introduced in most countries. Thereafter, a significant reduction of new asymptomatic and symptomatic COVID-19 cases occurred, although there were differences between countries according to the type and duration of the NPIs. In addition, the COVID-19 pandemic has been accompanied by significant variations in the global incidence of diseases due to the most common non-SARS-CoV-2 respiratory viruses and some bacteria. In this narrative review, the epidemiology of the most common non-SARS-CoV-2 respiratory infections during the COVID-19 pandemic is detailed. Moreover, factors that could have had a role in modifying the traditional circulation of respiratory pathogens are discussed. A literature analysis shows that NPIs were the most important cause of the general reduction in the incidence of influenza and respiratory syncytial virus infection in the first year of the pandemic, although the different sensitivity of each virus to NPIs, the type and duration of measures used, as well as the interference among viruses may have played a role in modulating viral circulation. Reasons for the increase in the incidences of Streptococcus pneumoniae and group A Streptococcus infections seem strictly linked to immunity debt and the role played by NPIs in reducing viral infections and limiting bacterial superimposed infections. These results highlight the importance of NPIs during pandemics, the need to monitor the circulation of infectious agents that cause diseases similar to those caused by pandemic agents, and the need to make efforts to improve coverage with available vaccines.

show abstract

Section: Reasons For Variations In Epidemiology Of Non-sars-cov-2 Vir...mentioning

confidence: 99%

Epidemiology of Respiratory Infections during the COVID-19 Pandemic

Principi

Autore

Ramundo

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…Urquidi et al demonstrated a positive correlation between full primary vaccination and consistent facemask usage, emphasizing the additional impact of facemasks in augmenting vaccine effectiveness to mitigate severe disease during periods of heightened viral circulation [ 14 , 15 ].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Sinopharm’s BBIBP-CorV Booster Vaccination against COVID-19-Related Severe and Critical Cases and Deaths in Morocco during the Omicron Wave

Belayachi,

Mhayi,

Majidi

et al. 2024

Vaccines

View full text Add to dashboard Cite

Objective: This study investigates the effectiveness of the 1st booster dose against COVID-19 severe and critical hospitalizations and deaths occurring due to the Omicron wave in Morocco. Participants/methods: This study uses nationally representative data on COVID-19 from 15 December 2021 to 31 January 2022. The aim is to investigate the effectiveness of the inactivated COVID-19 vaccine BBIBP-CorV (Sinopharm) 1st booster dose against the Omicron wave in Morocco using real-world data established from nationally representative statistics on COVID-19 cases, deaths and vaccinations. Statistical Analyses: The screening method was used to estimate vaccine effectiveness against COVID-19 severe or critical hospitalization and COVID-19-related deaths. The data were grouped by, age subgroup, sex, week, and geographical area and were analyzed using binary logistic regression with an offset for vaccine coverage. Results: The overall BBIBP-CorV VE estimate is 89% (95% CI 85 to 92) effective in curbing COVID-19 deaths, and 81% (95% CI 78 to 84 in curbing COVID-19 severe/critical hospitalizations. Death-related VE estimate was 86% (95% CI 81 to 90) for patients aged ≥65 years, 96% (95% CI 90 to 98) for those aged <65 years, 95% (95% CI 88 to 98) in no-risk factor patients, 91% (95% CI 85 to 94) with 1 risk factor, 90% (95% CI 83 to 95) with 2 risk factors, and 72% (95% CI 52 to 84) in patients with 3 risk factors and more. Severe/critical hospitalization VE estimate was 78% (95% CI 74 to 82) for patients aged ≥65 years, 87% (95% CI 82 to 90) for those aged <65 years, 86% (95% CI 80 to 90) in no-risk factor patients, 80% (95% CI 73 to 84) with 1 risk factor, 80% (95% CI 70 to 85) with 2 risk factors, and 80% (95% CI 68 to 86) in patients with 3 risk factors and more. Conclusions: BBIBP-CorV boosters are effective in increasing protection against the Omicron variant-related COVID-19 deaths and severe/critical hospitalizations. The protection is reduced with older age and higher risk factors. These findings emphasize the importance of targeted vaccination strategies for different demographic groups and underscore the protective benefits of the first booster BBIBP-CorV vaccine.

show abstract

“…Urquidi et al demonstrated a positive correlation between full primary vaccination and consistent facemask usage, emphasizing the additional impact of facemasks in augmenting vaccine effectiveness in mitigating severe disease during periods of heightened viral circulation (13,14).…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Sinopharm’s BBIBP-CorV Booster Vaccination Against COVID-19-Related Severe and Critical Cases and death in Morocco During the Omicron Wave

Belayachi,

Mhayi,

Majidi

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective : This study investigates the effectiveness of booster doses on the Omicron wave in Morocco against COVID-19 severe and critical hospitalizations and deaths; Participants/methods: This study uses nationally representative data on COVID-19 from 15 December 2021 to 31 January 2022. To investigate the effectiveness of the inactivated COVID-19 vaccine BBIBP-CorV (Vero Cells) Sinopharm booster doses on the Omicron wave in morocco by using real-world data established from nationally representative statistics on COVID-19 cases, deaths and vaccinations. Statistical Analyses : The screening method was used to estimate vaccine effectiveness against COVID-19 severe or critical hospitalization and COVID-19-related deaths. The data were grouped by, age subgroup, sex, week, and geographical area and were analyzed by using binary logistic regression with an offset for vaccine coverage. Results: The overall sinopharm VE estimate is 89% (95% CI 85 to 92) effective in curbing COVID-19 death, and 81% (95% CI 78 to 84 in curbing COVID-19 severe critical hospitalization. Death-related VE estimate was 86% (95% CI 81 to 90) for patients aged ⩾65 years, 96% (95% CI 90 to 98) for those aged < 65 years, 95% (95% CI 88 to 98) in no risk factor patient was, 91% (95% CI 85 to 94) with 1 risk factor ; 90% (95% CI 83 to 95) with 2 risk factors; 72% (95% CI 52 to 84) in patient with 3 risk factors and more. Severe critical hospitalization VE, estimate was 78% (95% CI 74 to 82) for patients aged ⩾65 years, 87% (95% CI 82 to 90) for those aged < 65 years, 86% (95% CI 80 to 90) in no risk factor patient was, 80% (95% CI 73 to 84) with 1 risk factor ; 80% (95% CI 70 to 85) with 2 risk factors; 80% (95% CI 68 to 86) in patient with 3 risk factors and more. Conclusions : Sinopharm Boosters are effective in increasing protection against Omicron variant-related COVID-19 death and severe critical hospitalization. The protection is reduced with older age and higher risk factors. These findings emphasize the importance of targeted vaccination strategies for different demographic groups and underscore the protective benefits of the third booster Sinopharm vaccine.

show abstract

The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study

Cited by 4 publications

References 29 publications

Epidemiology of Respiratory Infections during the COVID-19 Pandemic

Epidemiology of Respiratory Infections during the COVID-19 Pandemic

Effectiveness of Sinopharm’s BBIBP-CorV Booster Vaccination against COVID-19-Related Severe and Critical Cases and Deaths in Morocco during the Omicron Wave

Effectiveness of Sinopharm’s BBIBP-CorV Booster Vaccination Against COVID-19-Related Severe and Critical Cases and death in Morocco During the Omicron Wave

Contact Info

Product

Resources

About